Search peptides, terms, sources/
Metabolic and incretin

Liraglutide

Earlier-generation GLP-1 receptor agonist studied in type 2 diabetes and weight management. UK prescription-only medicine; licence status depends on the brand.

UK status checked . Evidence last reviewed . By the PeptGuru editorial team (Astute Management).

Evidence grade: best single recorded finding

How grading works

Best recorded finding: Moderate evidence (level 3 of 4 on our scale)

This grades the evidence behind one recorded finding. It does not rate the medicine.

2 findings at this grade. See all findings

These labels summarise the recorded evidence and the UK regulatory position. They are not recommendations, and none of them means a product is safe to obtain or use.

UK status
Licensed UK medicineChecked
Best study type
Human trials3 human trials

What is Liraglutide?

Liraglutide is a synthetic GLP-1 receptor agonist studied in type 2 diabetes, weight management and cardiovascular outcomes. In the UK it is a prescription-only medicine, with licence status that depends on the specific brand. The research includes large randomised controlled trials.

It is an earlier-generation, shorter-acting copy of human GLP-1. The cardiovascular research was in adults with type 2 diabetes and high cardiovascular risk.

Class
GLP-1 receptor agonist, Incretin mimetic
Origin
Analogue / modified
UK status
Licensed UK medicine
Best study type
Human trials
Evidence last reviewed

How does Liraglutide work?

Liraglutide copies the natural hormone GLP-1 and binds the GLP-1 receptor. This makes the pancreas release insulin when blood sugar is high, slows stomach emptying and lowers appetite. A fatty-acid side chain keeps it in the blood longer than natural GLP-1, but not as long as later versions.

The mechanism in more detail

Liraglutide is a 31-amino-acid acylated analogue of human GLP-1, reported with approximately 97% sequence homology to the native hormone, modified with a fatty-acid side chain for albumin binding. This gives it a shorter duration of action than the longer-acting GLP-1 analogues developed later.

Liraglutide binds pancreatic and other GLP-1 receptors, increasing intracellular cyclic AMP and activating downstream signalling that alters beta-cell ion-channel activity and sensitises beta cells to glucose, increasing glucose-dependent insulin secretion. Research literature additionally reports liraglutide acting through appetite regulation, delayed gastric emptying, and effects on energy expenditure and lipid metabolism, mechanisms broadly shared across the GLP-1 receptor agonist class.

Classification and structure

Names
Liraglutide; Victoza (lower-dose, type 2 diabetes brand, discontinued in the UK); Saxenda (higher-dose, weight-management brand)
Class
GLP-1 receptor agonist Incretin mimetic
Origin
Analogue / modified
Structure
31-amino-acid acylated analogue of human GLP-1, reported with 97% amino-acid sequence homology to endogenous human GLP-1, modified with a fatty-acid (palmitoyl) side chain enabling albumin binding (a shorter half-life than the later semaglutide and tirzepatide analogues).
Routes used in the research
Subcutaneous injection in the SCALE and LEADER trials.How the substance was given in the studies cited on this page. This describes study methods only. It is not guidance on use.

What does the research show?

Liraglutide has 3 recorded research findings. Each shows how strong it is, the kind of study behind it, its source and its main limitation.

Findings by strength of evidence

3 findings

Counts recorded findings by grade. It does not rate the medicine.

Findings by strength of evidence
PreliminaryLimitedModerateStrongNot graded
01200

SCALE prediabetes progression trial Moderate

In a randomised trial of adults with prediabetes and obesity, subcutaneous liraglutide was superior to placebo at preventing progression to type 2 diabetes over approximately 3 years, following an initial 56-week weight-focused trial phase (SCALE Obesity and Prediabetes).

Study type
Human trial
Population
Adults with obesity and prediabetes.
Source
1 le Roux et al., 2017

Limitation: Sponsor-funded (Novo Nordisk).

Limitations in full

Sponsor-funded (Novo Nordisk). In the 160-week trial, 2% of the liraglutide group and 6% of the placebo group were diagnosed with diabetes; about half of participants completed the trial.

The LEADER outcomes trial Moderate

In the LEADER cardiovascular outcomes trial, liraglutide reduced the risk of major adverse cardiovascular events in adults with type 2 diabetes and high cardiovascular risk compared with placebo, over a median follow-up of 3.8 years.

Study type
Human trial
Population
Adults with type 2 diabetes and high cardiovascular risk, multicentre, phase 3b/4.
Source
2 Marso et al., 2016

Limitation: Sponsor-funded.

Limitations in full

Sponsor-funded. Population was people with type 2 diabetes, not a general weight-management group.

SCALE 56-week weight trials Limited

Liraglutide (as an adjunct to diet and exercise) produced significant weight loss compared with placebo in adults with obesity, forming the evidence base for its weight-management licence (SCALE programme, 56-week core trials).

Study type
Human trial
Population
Adults with obesity or overweight with comorbidity.
Source
3 Pi-Sunyer et al., 2015

Limitation: Sponsor-funded (Novo Nordisk). 3,731 adults were randomised for 56 weeks; mean weight loss was 8.4 kg on liraglutide against 2.8 kg on placebo.

What safety findings have been reported?

3 safety findings are recorded for Liraglutide. A short list does not mean a substance is safe; it reflects what has been studied and reported.

Rodent thyroid C-cell tumours

Liraglutide causes thyroid C-cell tumours (medullary thyroid carcinoma, MTC) at clinically relevant exposures in rodent (rat and mouse) studies in both sexes. The human relevance of this rodent finding has not been established by clinical or non-clinical studies, and intensive monitoring of calcitonin (a marker for MTC) during the liraglutide human clinical development programme did not show an effect on human calcitonin levels. Liraglutide nonetheless carries a boxed warning for MTC risk based on the rodent signal and is contraindicated in patients with a personal or family history of MTC or multiple endocrine neoplasia syndrome type 2 (MEN 2). Post-marketing case reports of MTC in patients treated with a GLP-1 receptor agonist exist but are described in the source reviewed as insufficient to establish or exclude a causal relationship in humans.

Source
4 eMC

Acute pancreatitis in SCALE

A numerically higher rate of acute pancreatitis was observed in liraglutide treatment arms versus placebo across the SCALE programme, though absolute rates were reported as low. A causal relationship between liraglutide treatment and pancreatitis has not been established in the source reviewed.

Source
4 eMC

Class-wide gastrointestinal effects

Gastrointestinal effects (nausea, vomiting, diarrhoea) are the most common adverse effects reported for GLP-1 receptor agonists as a class, including liraglutide. MHRA guidance flags rare acute pancreatitis (including rare fatal reports across the class) and counterfeit/falsified product risks as class-wide safety concerns.

Source
5 MHRA, 2026

What is Liraglutide's UK regulatory status?

Licensed UK medicineChecked Source: 4 eMCWhat this label means
Marketing authorisation
Licensed, but with an important brand-specific complication. Victoza (the lower-dose type 2 diabetes brand) has been discontinued by its manufacturer and, per a House of Commons Library research briefing, has been unavailable in the UK since 2023. Saxenda (the higher-dose weight-management brand) remains licensed, authorised on 23 March 2015, though supply has been described as constrained at points; several generic liraglutide products are now listed on the eMC (checked 14 November 2026).
Prescription status
Prescription-only medicine (POM), for the currently-marketed Saxenda brand and any equivalent generic products.
Medicine class
Licensed medicinal product. Status is brand-dependent; MHRA's own class-wide guidance states liraglutide status is brand specific and should be checked against the product information leaflet, not generalised across all liraglutide-containing products.
MHRA position
MHRA-authorised historically for both type 2 diabetes (Victoza) and, at higher dose, weight management (Saxenda) alongside reduced-calorie diet and increased physical activity. Victoza's discontinuation is a commercial/supply event, not a licence withdrawal, per the sources reviewed; unavailable in practice is a different fact from unlicensed in principle.
Authorised use
Weight management alongside a reduced-calorie diet and increased physical activity, in adults with a BMI of 30 or above, or 27 or above with a weight-related condition, and in adolescents aged 12 and over with obesity and a body weight above 60 kg. Type 2 diabetes mellitus (the diabetes brand is no longer supplied in the UK). NICE TA664 covers liraglutide for weight management.
Research use
Not applicable in the unlicensed research-chemical sense. Liraglutide is a licensed medicine class.
Other restrictions
MHRA's GLP-1-class guidance explicitly instructs that liraglutide's exact current status should be checked against the specific product's information leaflet rather than assumed, a direct instruction from the regulator itself.

These labels summarise the recorded evidence and the UK regulatory position. They are not recommendations, and none of them means a product is safe to obtain or use.

References

5 sources, numbered as cited above. Each has its own page with its limitations and everything that cites it.

  1. le Roux CW, Astrup A, Fujioka K, Greenway F, et al. (2017). 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. The Lancet, 389(10077):1399-1409Human clinical trial, RCT · DOI 10.1016/S0140-6736(17)30069-7 · PMID 28237263 · Original ↗
  2. Marso SP, Daniels GH, Brown-Frandsen K, et al. (2016). Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER). New England Journal of MedicineHuman clinical trial, RCT · DOI 10.1056/NEJMoa1603827 · Original ↗
  3. Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, Lau DC, le Roux CW, Violante Ortiz R, Jensen CB, Wilding JP; SCALE Obesity and Prediabetes NN8022-1839 Study Group (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1):11-22Human clinical trial, RCT · DOI 10.1056/NEJMoa1411892 · PMID 26132939 · Original ↗
  4. Novo Nordisk Limited Liraglutide (weight-management product): Summary of Product Characteristics, eMC. electronic Medicines Compendium (eMC), Summary of Product Characteristics: Saxenda · Original ↗
  5. MHRA (UK government body) (2026). GLP-1 medicines for weight loss and diabetes: what you need to know. GOV.UKGovernment guidance · Original ↗

Questions about Liraglutide

What is Liraglutide?

Liraglutide is a synthetic GLP-1 receptor agonist studied in type 2 diabetes, weight management and cardiovascular outcomes. In the UK it is a prescription-only medicine, with licence status that depends on the specific brand. The research includes large randomised controlled trials. Read what it is.

Is Liraglutide licensed in the UK?

PeptGuru records Liraglutide's UK status as: Licensed UK medicine. The licensed products and their approved uses are listed in the UK status section. UK status checked 14 November 2026. This is a record of regulation, not a recommendation. Read the UK status.

What does the research on Liraglutide show?

PeptGuru records 3 research findings for Liraglutide: 3 from human trials. Each finding has its own evidence grade, source and main limitation. Read the research findings.

What safety findings have been reported for Liraglutide?

3 safety findings are recorded, including: rodent thyroid C-cell tumours; acute pancreatitis in SCALE; class-wide gastrointestinal effects. Each is cited to its source. A short list does not mean a substance is safe. Read the safety findings.

Where are the sources for Liraglutide?

All 5 sources are listed in the references, each with a link to the original study or regulator document and its own source page on PeptGuru. See the references.

Review record and change log

Last reviewed
Evidence last reviewed
UK status checked
Reviewed by
PeptGuru editorial team
  • Correction · The safety source is now the official UK product information (Summary of Product Characteristics) for liraglutide's weight-management product, replacing an uncited monograph reference.
  • Correction · The SCALE trial reference now carries its DOI and PubMed ID (Pi-Sunyer et al., NEJM 2015).
  • Regulatory update · UK status re-checked against the official product information. Several generic liraglutide products are now listed; adolescent weight management added to the licensed uses.

How findings are graded: the grading method. All changes.

  • Semaglutide

    GLP-1 receptor agonist studied in type 2 diabetes, weight management and cardiovascular outcomes. UK prescription-only medicine; studied in large randomised trials.

    Metabolic and incretinHuman trialsEvidence reviewed
    StrongLicensed UK medicine
  • Tirzepatide

    Dual GIP and GLP-1 receptor agonist studied in type 2 diabetes and weight management. UK prescription-only medicine; studied in large randomised trials.

    Metabolic and incretinHuman trialsEvidence reviewed
    StrongLicensed UK medicine
  • Mazdutide

    Not authorised in the UK; approved in China. Peptide that activates glucagon and GLP-1 receptors, studied in phase 3 trials in Chinese adults.

    Metabolic and incretinHuman trialsEvidence reviewed
    StrongNot licensed in the UK
  • RetatrutideLY3437943

    Investigational triple GIP, GLP-1 and glucagon receptor agonist studied for weight management. Not licensed in the UK; studied in a Phase 2 trial.

    Metabolic and incretinHuman trialsEvidence reviewed
    ModerateNot licensed in the UK

Compare Liraglutide with Semaglutide

Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.